Drugs / Umbilical Cord Blood Mononuclear Cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01354483 | Sep 2011 → Sep 2013 | spinal cord injury | China Spinal Cord Injury Network | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03979742 | Feb 2022 → Dec 2024 | spinal cord injury | StemCyte, Inc. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01046786 Comparator | Jan 2010 → Oct 2013 | spinal cord injury | China Spinal Cord Injury Network | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Blood Mononuclear Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03979742 ↗ |
| Modality | Cell therapy | “umbilical cord blood mononuclear cell transplant” NCT01354483 ↗ |
| Route | Other | “Intraspinal injection of 1.6 million cord blood mononuclear cell” NCT01046786 ↗ |